SETD2 in MLL-rearranged leukemia - a complex case

Anna Skucha; Jessica Ebner; Florian Grebien

doi:10.1080/23723556.2018.1503492

SETD2 in MLL-rearranged leukemia - a complex case

Mol Cell Oncol. 2018 Aug 13;5(4):e1503492. doi: 10.1080/23723556.2018.1503492. eCollection 2018.

Authors

Anna Skucha^{1

2}, Jessica Ebner², Florian Grebien^{2

3}

Affiliations

¹ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
² Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
³ Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Austria.

Abstract

Oncogenic MLL-fusion proteins often hijack essential molecular mechanisms during leukemogenesis. The histone methyltransferase SETD2 was implicated in the regulation of transcription, DNA damage and other cellular processes. Recent studies identified a critical role for SETD2 in MLL-rearranged leukemia. These results may help to unravel important functions of SETD2 in hematopoiesis.

Keywords: AML; MLL-rearranged leukemia; SETD2; fusion proteins.

Grants and funding

This work was supported by the FP7 People: Marie-Curie Actions [289611];H2020 European Research Council [636855/StG];Österreichische Forschungsförderungsgesellschaft [857935];